Gaithersburg, MD — September 15, 2025 — Leads & Copy — Altimmune, Inc. (Nasdaq: ALT) has appointed Linda M. Richardson as Chief Commercial Officer, effective September 16, 2025. Richardson brings over 30 years of experience in sales, marketing, and business development across various therapeutic areas, including metabolic disease and hepatology.
According to Vipin K. Garg, Ph.D., President and CEO of Altimmune, Richardson’s addition is a strategic move as the company approaches Phase 3 development of pemvidutide in MASH. Richardson expressed enthusiasm for pemvidutide’s potential in hepato-metabolic disease and its ability to improve the lives of patients with MASH.
Richardson previously served as Chief Commercial Officer at Intercept Pharmaceuticals and held senior positions at Chimerix, Sanofi, Reliant Pharmaceuticals, and GSK. She holds a bachelor’s degree in English from the University of Pennsylvania.
In connection with her appointment, Richardson will receive options to purchase 278,000 shares of Altimmune’s common stock and 96,000 restricted stock units, vesting over four years, subject to continued employment.
Altimmune focuses on developing peptide-based therapeutics for liver and cardiometabolic diseases, with pemvidutide as its lead product candidate for MASH, Alcohol Use Disorder, Alcohol-associated Liver Disease, and obesity.
Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Source: Altimmune, Inc.
